Report Categories
View AllRecent Articles
View All
AIRelated Layoffs May Not Boost Stocks as Investors Expect Data Suggests
Tech Stocks Lift Indices to Fresh Highs as Broader Market Struggles Following Inflation Report
National Fuel Gas Co Draws Analyst Attention Amid Natural Gas Sector Volatility
Plus500 Confirms Guidance as Quarterly Revenue Rises 11
Q2 Holdings Combines Banking Growth with Practical AI Tools Amid Turnaround Potential
Deel Announces Stablecoin Salary Payouts for Global Workforce
Japans Megabanks Enjoy Record Profits but Analysts Warn of Slowing Growth Amid Rising Risks
Vestas Wind Systems Shares Decline After Company Warns Margins at Low End of Guidance
Berkshire Hathaway Rebuilds Airline Exposure With 26 Billion Delta Air Lines Stake
Federal Reserve May Face Limited Justification for Interest Rate Cuts as Jobs Report Highlights Persistent Cost of Living Pressures
Lennar LEN Q1 2026 Earnings EPS Miss Highlights Ongoing Housing Market Headwinds
Ashland Inc ASH Q1 2026 Earnings Narrow EPS Miss Masks Underlying Resilience Shares Rally
ENTX Q1 2026 Earnings NarrowerthanExpected Loss Reflects Cost Discipline Amid PreRevenue Stage
TME Q1 2026 Earnings EPS Beats Estimates Amid Market Headwinds
DVS Q4 2025 Earnings Silver Developer Reports WiderThanExpected Loss Amid PreRevenue Phase
Barnwell Industries Q4 2024 Earnings Reports Loss of 019 Per Share Stock Rises 091
Lifeward Ltd LFWD Surges Over 11 as Shares Test Key Resistance
ASGN Incorporated ASGN Plunges Over 50 Key Support Levels and Potential Scenarios After Massive SellOff
Medalist Diversified MDRR Drops Sharply Holds Above Key Support Level
YD Bio Warrants YDESW Hold Steady at 041 as Range Tightens
GlucoTrack Inc GCTK Rallies 823 as Shares Test Key Resistance Level
Japan to Welcome First Crude Cargo via Strait of Hormuz Since Regional Conflict Escalated
Microsoft Flags 190B Capital Spending Need by 2026 Amid Memory Price Surge
Travel Insurance for Foreign Trips Whats Covered and Whats Excluded
APEC Meeting Highlights Persistent USChina Trade Divergence After TrumpXi Summit
Canaccord Lowers Regeneron Price Target After Disappointing Phase 3 Trial Outcome